Relay Therapeutics, Inc.
RLAY
Rank in Stocks
#4085
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Share Price
$18.21
Market Cap
$3.99B
Change (1 day)
6.55%
Change (1 year)
155.04%
Country
US
Trade Relay Therapeutics, Inc. (RLAY)
Category
Healthcare
Revenue for Relay Therapeutics, Inc. (RLAY)
Revenue in Jun 2026 TTM: $10.35M
According to Relay Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is $10.35M. In 2023 the company made a revenue of $25.55M an increase over the revenue in the year 2022 that was $1.38M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Relay Therapeutics, Inc. from 2018 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $10.35M | 3.43% |
| 2024 | $10.01M | -60.83% |
| 2023 | $25.55M | 1,749.82% |
| 2022 | $1.38M | -54.41% |
| 2021 | $3.03M | -96.34% |
| 2020 | $82.65M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 121,873.91% |
US
|
|
| $2.23B | 21,426.57% |
US
|
|
| $15.74B | 152,019.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 58,076.69% |
NL
|
